Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05552755 · ClinicalTrials.gov registry record · Phase 1

Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)

A Phase 1 study of Familial Adenomatous Polyposis, sponsored by Recursion Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
67
Enrollment target
17
Study locations

NCT05552755 is a Phase 1 study of Familial Adenomatous Polyposis that is actively recruiting participants, run by Recursion Pharmaceuticals. The registered enrollment target is 67 participants, below the 242-participant average among 10 other Familial Adenomatous Polyposis trials with a reported enrollment target (72% lower). The trial reports 17 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05552755, a Phase 1 study of Familial Adenomatous Polyposis, is actively recruiting participants, sponsored by Recursion Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
67 participants
Enrollment target
17
Study locations

Study Summary

This is a multicenter, two-part trial in participants with FAP.

Interventions

  • DRUG Placebo
  • DRUG REC-4881

Study Locations (17)

Arizona

  • Mayo Clinic - Scottsdale - Scottsdale
  • Del Sol Research Management - Tucson

Florida

  • GI Pros - Naples
  • Digestive and Liver Center of Florida - Orlando

Tennessee

  • Gastro One-8110 Walnut Rs - Cordova
  • Vanderbilt Digestive Center - Nashville

Texas

  • Genetic Cancer Prevention Clinic - UT Southwestern - Dallas
  • MD Anderson Cancer Center - Houston

California

  • Medical Associates Research Group - San Diego

Indiana

  • Gastroenterology Health Partners, PLLC - New Albany

Louisiana

  • Tandem Clinical Research - Marrero

Michigan

  • Corewell Health (Spectrum Health Hospitals Colorectal Cancer Multis) - Grand Rapids

Trial Details

FieldValue
Enrollment Target 67 participants
Start Date 2023-07-10
Est. Completion 2026-07
Phase Phase 1

Sponsor

Recursion Pharmaceuticals

6 total trials

What the Registry Record Tells You About NCT05552755

The ClinicalTrials.gov registry entry for NCT05552755 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 10 other Familial Adenomatous Polyposis trials with a reported enrollment target (72% lower). The listed sponsor is Recursion Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Familial Adenomatous Polyposis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05552755 reports 17 study locations spanning 13 distinct geographic areas - top geographies include Arizona, Florida, Tennessee.

Frequently Asked Questions

What is clinical trial NCT05552755 about?

NCT05552755 is a clinical study titled "Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)". This is a multicenter, two-part trial in participants with FAP.

What is the current status of trial NCT05552755?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2023-07-10. Estimated completion is 2026-07.

What conditions does trial NCT05552755 study?

This clinical trial studies the following conditions: Familial Adenomatous Polyposis.

What interventions are being tested in trial NCT05552755?

The interventions under investigation include: Placebo (DRUG), REC-4881 (DRUG).

Who is sponsoring clinical trial NCT05552755?

This trial is sponsored by Recursion Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05552755 being conducted?

This trial has 17 study locations across Arizona, California, Florida, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Familial Adenomatous Polyposis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.